IMM Immupharma Plc

TIDMIMM

RNS Number : 6483Z

Immupharma PLC

20 March 2012

FOR IMMEDIATE RELEASE 20 MARCH 2012

ImmuPharma plc

Notification of Full Year Results

Date: 27 March 2012

ImmuPharma plc (AIM: IMM), the specialist drug development company, is scheduled to announce its Preliminary Results for the year ended 31 December 2011 on Tuesday 27 March 2012.

A lunch briefing for analysts and private client brokers will be held at 12.00pm on the day of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

- Ends -

For further information please contact:

 
 ImmuPharma plc                        + 44 (0) 20 7152 4080 
 Dimitri Dimitriou, Chief Executive 
  Officer 
 Lisa Baderoon, Head of Investor 
  Relations 
  lisa.baderoon@immupharma.com          + 44 (0) 7721 413496 
 
 Buchanan                              + 44 (0) 20 7466 5000 
 Mark Court, Jessica Fontaine 
 
 Panmure, Gordon & Co., NOMAD 
  & Broker                              +44 (0) 20 7459 3600 
 Andrew Burnett 
 Rakesh Sharma 
 
 Espirito Santo Investment Bank         +44 (0) 20 7456 9191 
 James Bromhead 
 Richard Crawley 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORKMGMFNLMGZZM

Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024